Vitamin D3 Supplementation in Overweight/Obese Pregnant Women: No Effects on the Maternal or Fetal Lipid Profile and Body Fat Distribution-A Secondary Analysis of the Multicentric, Randomized, Controlled Vitamin D and Lifestyle for Gestational Diabetes Prevention Trial (DALI).

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

The researchers aimed to assess the effects of vitamin D3 supplementation in pregnancy versus placebo on maternal and fetal lipids.

Linear regression models were used to assess effects of vitamin D on maternal and cord blood lipids.

Why It Was Studied

Both maternal vitamin D deficiency and maternal obesity contribute to metabolic derangements in pregnancy.

Main inclusion criteria were: women <20 weeks’ gestation, BMI ≥ 29 kg/m2.

Who Took Part

PubMed tags the participants as women only.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

What Was Measured

Assessments were performed <20, 24−28 and 35−37 weeks and at birth.

The subject headings attached to it are Body Fat Distribution, Cholecalciferol, Cholesterol, LDL, Diabetes, Gestational, Dietary Supplements, Fatty Acids, Nonesterified and Ketone Bodies.

The authors tagged it with the keywords birth outcomes, cord blood, free fatty acids, lipids, obesity pregnancy and overweight.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

The publication is from 2022 (Nutrients), a journal based in Switzerland.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.